Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets
作者： Dinesh K. Hirenallur-S , Neil D. Detweiler , Steven T. Haworth , Jeaninne T. Leming , John B. Gordon
关键词:
摘要: AbstractThe development of pulmonary arterial hypertension (PAH) in pediatric patients has been linked to the production arachidonic acid metabolite, thromboxane A2 (TxA2). The present study evaluated therapeutic effect furegrelate sodium, a synthase inhibitor, on PAH neonatal piglet model. Three-day-old piglets were exposed 21 days normoxia (N; 21% FIO2) or chronic hypoxia (CH; 10% FIO2). A third group received oral TxA2 (3 mg/kg, 2 3 times daily) at induction CH. In vivo hemodynamics confirmed 2.55-fold increase vascular resistance index (PVRI) CH (104±7 WU) compared N (40±2 WU). treated twice daily with failed show improved PVRI, but three lowered elevated PVRI by 34% 69±5 WU and ameliorated right ventricular hypertrophy. Microfocal X-ray computed tomography ...
sagepub.com
uchicago.edu
jstor.org 
sci-hub.se 参考文章(35)
Duane B. Lakings, Janice M. Friis, Cynthia M. Lunan, James T. VanderLugt, J. Scott Mohrland, Pharmacokinetics of furegrelate after oral administration to normal humans. Pharmaceutical Research. ,vol. 6, pp. 53- 57 ,(1989) , 10.1023/A:1015899602741
Christina Perneby, Elisabeth Granström, Olof Beck, Desmond Fitzgerald, Brendan Harhen, Paul Hjemdahl, Optimization of an Enzyme Immunoassay for 11-Dehydro-Thromboxane B2 in Urine Thrombosis Research. ,vol. 96, pp. 427- 436 ,(1999) , 10.1016/S0049-3848(99)00126-7
M. Beghetti, Current treatment options in children with pulmonary arterial hypertension and experiences with oral bosentan. European Journal of Clinical Investigation. ,vol. 36, pp. 16- 24 ,(2006) , 10.1111/J.1365-2362.2006.01681.X
Rajbabu Pakala, James T. Willerson, Claude R. Benedict, Effect of Serotonin, Thromboxane A2, and Specific Receptor Antagonists on Vascular Smooth Muscle Cell Proliferation Circulation. ,vol. 96, pp. 2280- 2286 ,(1997) , 10.1161/01.CIR.96.7.2280
Candice D. Fike, Yongmei Zhang, Mark R. Kaplowitz, Thromboxane inhibition reduces an early stage of chronic hypoxia-induced pulmonary hypertension in piglets Journal of Applied Physiology. ,vol. 99, pp. 670- 676 ,(2005) , 10.1152/JAPPLPHYSIOL.01337.2004
Carina L. Bos, Dick J. Richel, Tita Ritsema, Maikel P. Peppelenbosch, Henri H. Versteeg, Prostanoids and prostanoid receptors in signal transduction The International Journal of Biochemistry & Cell Biology. ,vol. 36, pp. 1187- 1205 ,(2004) , 10.1016/J.BIOCEL.2003.08.006
S Fuse, T Kamiya, Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease. Circulation. ,vol. 90, pp. 2952- 2955 ,(1994) , 10.1161/01.CIR.90.6.2952
Rajbabu Pakala, Claude R. Benedict, Effect of serotonin and throm☐ane A2 on endothelial cell proliferation: Effect of specific receptor antagonists Journal of Laboratory and Clinical Medicine. ,vol. 131, pp. 527- 537 ,(1998) , 10.1016/S0022-2143(98)90061-0
M.A. Wynalda, W.F. Liggett, F.A. Fitzpatrick, Sodium 5-(3'-pyridinylmethyl) benzofuran-2-carboxylate (U-63557A), a new selective thromboxane synthase inhibitor: intravenous and oral pharmacokinetics in dogs and correlations with ex-situ thromboxane B2 production Prostaglandins. ,vol. 26, pp. 311- 324 ,(1983) , 10.1016/0090-6980(83)90098-9
M. Hamberg, J. Svensson, B. Samuelsson, Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 72, pp. 2994- 2998 ,(1975) , 10.1073/PNAS.72.8.2994